Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of GW642444M - A Randomized, Double Blind, Placebo Controlled, Parallel-Group, 7 Day Repeat Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled Dose of GW642444M From a Novel Dry Powder Device in Healthy Japanese Male Subjects.

Next Previous
Trial Profile

Phase I Study of GW642444M - A Randomized, Double Blind, Placebo Controlled, Parallel-Group, 7 Day Repeat Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled Dose of GW642444M From a Novel Dry Powder Device in Healthy Japanese Male Subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vilanterol (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors GSK

Most Recent Events

  • 25 Aug 2009 Actual end date (1 Nov 2008) added as reported by ClinicalTrials.gov (NCT00964249).
  • 25 Aug 2009 Actual end date (1 Nov 2008) added as reported by ClinicalTrials.gov (NCT00964249).
  • 25 Aug 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov (NCT00964249).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top